TalkbackShare your ideas and expertise on this topic
How Eli Lilly Waved Goodbye to $3.1 Billion
-
RobertCD10/27/08 Reported as spam1
RE: How Eli Lilly Waved Goodbye to $3.1 Billion
Jim,
I think what they are saying is that the exceptional (hopefully) non-recurring charge expressed as a percentage of current quarter sales is not a meaningful ratio. The meaningful number would be the cummulative charge to date for Zyprexa legal costs as a percentage of cummulative sales to date of Zyprexa. Unfortuantaly however interesting there is no legal requirement to disclose this. It is probably possible to compute if you are interested... but I don't have time to wade through several years of historic accounting data.
RobertD
- The following tags are supported in BNET comments:
- <b></b> <i></i> <u></u> <pre></pre>